

INPLASY

The comparative effect of monotherapies for male androgenetic alopecia: a protocol for network meta-analysis study

INPLASY202410029

doi: 10.37766/inplasy2024.1.0029

Received: 08 January 2024

Published: 08 January 2024

Corresponding author:

Aditya Gupta

agupta@mediproberesearch.com

Author Affiliation:

Mediprobe Research Inc.

Gupta, AK¹; Bamimore, MA².

ADMINISTRATIVE INFORMATION

Support - None.

Review Stage at time of this submission - Formal screening of search results.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY202410029

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 08 January 2024 and was last updated on 08 January 2024.

INTRODUCTION

Review question / Objective The objective of the proposed study is to compare the relative effect of monotherapies for male AGA by conducting NMAs of relevant outcomes.

Rationale The evidence base pertaining to efficacy of therapies for androgenetic alopecia (AGA) is ever expanding; network meta-analyses (NMAs) are therefore relevant as more empirical data gets published. Statistical evidence on monotherapies' relative efficacy would better guide the conduct of future research and clinical decision making.

Condition being studied Male androgenetic alopecia.

METHODS

Participant or population Men with androgenetic alopecia.

Intervention Relevant monotherapies used to treat androgenetic alopecia in men.

Comparator Placebo/vehicle or other active comparators (i.e., relevant monotherapies used to treat androgenetic alopecia in men).

Study designs to be included The proposed study will include data from trial studies.

Eligibility criteria Only trial evidence published in English language will be eligible.

Information sources Various information sources will be used including PubMed.

Main outcome(s) Our two outcomes of interest will be 6-month change in total and terminal hair density.

Additional outcome(s) None.

Quality assessment / Risk of bias analysis Assessment of evidence quality will be conducted with Cochrane Collaboration's risk of bias tools.

Strategy of data synthesis The collated data will guide the finalized analyses.

Subgroup analysis None.

Sensitivity analysis None.

Country(ies) involved Canada.

Keywords androgenetic alopecia; network meta-analyses; systematic review.

Contributions of each author

Author 1 - Aditya Gupta.

Email: agupta@mediproberesearch.com

Author 2 - Mary Bamimore.

Email: mbamimor@alumni.uwo.ca